The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2014, Pages 39-44

  Kurita, Takashi ^a   Yasuda, Shinsuke ^a   Oba, Koji ^b   Odani, Toshio ^a   Kono, Michihito ^a   Otomo, Kotaro ^a   Fujieda, Yuichiro ^a   Oku, Kenji ^a   Bohgaki, Toshiyuki ^a   Amengual, Olga ^a   Horita, Tetsuya ^a   Atsumi, Tatsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Dermatomyositis; Interstitial; Lung diseases; Polymyositis; Tacrolimus

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; MALE; POLYMYOSITIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; STEROID THERAPY; TREATMENT DURATION;

EID: 84928734519     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu166     Document Type: Article

References (20)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
2. Marie I, Hatron PY, Dominique S, Cherin P et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011;63:3439-47.
3. Chen IJ, Jan Wu YJ, Lin CW et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009;28:639-46.
4. Ye S, Chen XX, Lu XY et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007;26:1647-54.
5. Sato S, Hirakata M, Kuwana M et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52:1571-6.
6. Yamasaki Y, Yamada H, Yamasaki M et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007;46:124-30.
7. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52: 2439-46.
8. Takada K, Nagasaka K, Miyasaka N. Polymyositis/ dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005;38:383-92.
9. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341: 758-60.
10. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000;7:731-48.
11. Webster AC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810.
12. Haddad EM, McAlister VC, Renouf E et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006 Oct 18;(4):CD005161.
13. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graftversus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-8.
14. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.
15. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006;54:597-613.
16. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993-2000.
17. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-60.
18. Fujisawa T, Suda T, Nakamura Y et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005;32:58-64.
19. Kurasawa K, Nawata Y, Takabayashi K et al. Activation of pulmonary T cells in corticosteroid-resistant and-sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002;129:541-8.
20. Kameda H, Nagasawa H, Ogawa H et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32:1719-26.